Relic Technologies Ltd

Relic Technologies Limited trading window closed from October 01, 2026; to reopen after 48 hours of conclusion of the Board Meeting approving Unaudited Financial Results (Standalone and Consolidated) for the quarter ended September 30, 2026.

AGM Details

• AGM held on 13 August 2026 at 12:30 PM via Video Conferencing/OAVM.
• Remote e-voting period: 10–12 August 2026.
• Voting cut-off date: 6 August 2026.

Ordinary resolutions

• Item 1: Adoption of standalone and consolidated financial statements; passed.
• Item 2: Re-appointment of Kunal Gandhi as Director; passed.
• Item 3: Appointment of Radhika Shriram as Non-Executive Director; passed.
• Item 4: Appointment of Sachin Srivastava as Director; passed.

Special resolutions

• Item 5: Appointment of Sachin Srivastava as Whole Time Director and CEO; passed.
• Item 6: Approval for material related party transactions with Truhealthy Wellness Private Limited; passed.
• Item 7: Approval for Employee Stock Option Plan (ESOP) for the Company; passed.
• Item 8: Extension of ESOP 2025 to employees of subsidiary companies; passed.

Director changes

• Re-appointment of Kunal Gandhi as Director (retiring by rotation); passed.
• Ms. Radhika Shriram appointed as Non-Executive Director; passed.
• Sachin Srivastava appointed as Director and later as Whole Time Director & CEO.

Related party transactions

• RPT with Truhealthy Wellness Private Limited (subsidiary) approved; value not disclosed.

AGM Details

• Held on 13 August 2026, 12:30 PM–1:20 PM via VC/OAVM.
• Venue deemed at registered office.
• Remote e-voting: Aug 10–12, 9:00 AM–5:00 PM.
• Quorum present via video conference.
• Proxy facility not available; no proxies counted.

Resolutions Proposed

• Ordinary: Adopt audited standalone and consolidated financial statements for FY26.
• Ordinary: Re-appoint director retiring by rotation.
• Special: Appoint Ms. Radhika Shriram as Non-Executive Director.
• Special: Appoint Mr. Sachin Srivastava as Director.
• Special: Appoint Mr. Sachin Srivastava as Whole-Time Director and CEO.
• Special: Approve material related party transactions with Truhealthy Wellness Private Limited.
• Special: Approve ESOP for the Company.
• Special: Extend ESOP 2025 benefits to employees of subsidiary companies.

Voting Status

• Voting results pending; Scrutinizer to submit report.
• Results to be displayed on company and stock exchange websites within 48 hours.

Director Changes

• Kunal Gandhi to continue as director, retiring by rotation.
• Radhika Shriram appointed as Non-Executive Director.
• Sachin Srivastava appointed as Director and Whole-Time Director/CEO.

Auditor & Related Parties

• No auditor appointments or changes announced.
• RPT with subsidiary Truhealthy Wellness Private Limited included as a special resolution.

ESOP and Related Approvals

• ESOP for the Company approved; extension to subsidiary employees.

Deviation status and utilisation

• No deviation in the use of funds raised from the preferential issue for the quarter.
• Audit Committee reviewed and confirmed alignment with the objects.
• Fundraising dates: 5 April 2025 (equity); 13 December 2025 (warrant conversion to equity).
• Total proceeds raised: Rs 1317.50 Lakhs in equity; Rs 374.98 Lakhs for warrants.
• Utilisation status as of 30/06/2026: cumulative Rs 625.50 Lakhs utilised.
• Monitoring agency: Not applicable.
• There is no deviation or variation per the quarter's report.

Consolidated results

• Consolidated revenue from operations for the quarter ended June 30, 2026: 35.49 lakhs.
• Total consolidated income for the quarter: 57.86 lakhs.
• Total consolidated expenses: 162.07 lakhs.
• Net profit after tax for the quarter: loss of 102.75 lakhs.
• Basic and diluted EPS stood at -1.16 each.
• Total comprehensive income for the period: loss of 101.28 lakhs.
• Note: commenced revenue from trading activities in pharmaceuticals, nutraceuticals, wellness, healthcare, chemicals.

Financial results and revenue initiation

• Unaudited standalone and consolidated quarterly results for quarter ended June 30, 2026 approved.
• Limited Review Reports with unmodified opinion issued for both standalone and consolidated results.
• Revenue from operations commenced in quarter ended June 30, 2026 via trading activities in pharmaceuticals and related products.

Meeting Details

• Board meeting scheduled on August 13, 2026; time and venue not disclosed.

Key Agenda Items

• Consider unaudited standalone and consolidated Q1 2026 results for quarter ended June 30, 2026 with Limited Review Report.

Other Notes

• Trading window closed from July 1, 2026 until 48 hours after results are declared.

Dematerialisation status and certificate actions

• Securities received for dematerialisation up to 30 June 2026 were confirmed to depositories; listed on the exchange.
• Physical certificates dematerialised were mutilated and cancelled; depository's name substituted as registered owner within 15 days.